- Home
- DLO vs APLS Comparison
DLO vs APLS Comparison
Compare DLO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLO
- APLS
- Stock Information
- Founded
- DLO 2013
- APLS 2009
- Country
- DLO Uruguay
- APLS United States
- Employees
- DLO N/A
- APLS N/A
- Industry
- DLO Business Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- DLO Consumer Discretionary
- APLS Health Care
- Exchange
- DLO Nasdaq
- APLS Nasdaq
- Market Cap
- DLO 4.2B
- APLS 3.5B
- IPO Year
- DLO 2021
- APLS 2017
- Fundamental
- Price
- DLO $14.03
- APLS $25.34
- Analyst Decision
- DLO Buy
- APLS Buy
- Analyst Count
- DLO 9
- APLS 20
- Target Price
- DLO $13.18
- APLS $34.11
- AVG Volume (30 Days)
- DLO 4.0M
- APLS 2.1M
- Earning Date
- DLO 08-13-2025
- APLS 11-04-2025
- Dividend Yield
- DLO 3.75%
- APLS N/A
- EPS Growth
- DLO 9.30
- APLS N/A
- EPS
- DLO 0.48
- APLS N/A
- Revenue
- DLO $863,482,000.00
- APLS $754,649,000.00
- Revenue This Year
- DLO $39.28
- APLS $20.59
- Revenue Next Year
- DLO $29.45
- APLS N/A
- P/E Ratio
- DLO $28.39
- APLS N/A
- Revenue Growth
- DLO 22.02
- APLS 20.02
- 52 Week Low
- DLO $7.61
- APLS $16.10
- 52 Week High
- DLO $16.44
- APLS $39.51
- Technical
- Relative Strength Index (RSI)
- DLO 57.48
- APLS 45.79
- Support Level
- DLO $12.60
- APLS $27.26
- Resistance Level
- DLO $14.22
- APLS $28.97
- Average True Range (ATR)
- DLO 0.52
- APLS 0.99
- MACD
- DLO -0.17
- APLS -0.57
- Stochastic Oscillator
- DLO 54.55
- APLS 14.83
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.